Core Insights - GRI Bio, Inc. reported a cash position of $8.2 million as of December 31, 2025, and raised an additional $6.5 million in January 2026, strengthening its balance sheet to fund operations into Q1 2027 [1][4] - The company announced strong Phase 2a clinical data for GRI-0621 in idiopathic pulmonary fibrosis (IPF), reinforcing its clinical proof-of-concept and therapeutic differentiation [1][8] - GRI-0803, focused on autoimmune indications with high unmet need, is advancing through IND-enabling activities [1][8] Financial Summary - For the year ended December 31, 2025, GRI Bio reported a net loss of $12 million, with research and development expenses increasing to $6.8 million from $3.8 million in 2024, primarily due to the registration development program of GRI-0621 [5] - General and administrative expenses rose to $5.2 million in 2025 from $4.5 million in 2024, mainly due to increased personnel costs [6] Recent Highlights - The company raised approximately $14.5 million in gross proceeds in December 2025 and January 2026, ensuring a strong cash position to fund operations into Q1 2027 [8] - Positive Phase 2a topline data from the completed clinical study of GRI-0621 in IPF was announced, along with additional data demonstrating suppression of pro-fibrotic immune phenotypes [8] - New RNA-sequencing gene expression data was generated, showing a direct impact on the core biology of fibrosis and lung repair [8] - Plans to progress GRI-0803 into IND-enabling studies were advanced, expanding the company's pipeline in autoimmune diseases [8]